SPECT agent shows promise for imaging metastatic HER2 breast cancer

03/31/2014 | MolecularImaging.net

Indium-111 ABY-025 with SPECT could be used to pinpoint human epidermal growth factor receptor type 2 expression in metastatic breast cancer lesions, even with ongoing HER2-targeted treatment, according to data from a first-in-human trial reported in the Journal of Nuclear Medicine. Rapid clearance allowed for production of high-contrast images within four to 24 hours, and low hepatic uptake could allow for better imaging of liver lesions than a previous agent.

View Full Article in:

MolecularImaging.net

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA
Neurovascular Intervention Product Sales Rep, North East
ASAHI INTECC
Multiple Locations, SL_Multiple Locations
Vice President of Regulatory Affairs
Pentec Health
Boothwyn, PA
Sr Coordinator Clinical Research (US/TA/00/0073/SL) - 1400000AQX
Abbott
Santa Clara, CA
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA